Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Jason Mouabbi(The University of Texas MD Anderson Cancer Center), Ayşegül A. Şahin(The University of Texas MD Anderson Cancer Center), Amrit S. Gonugunta(The University of Texas MD Anderson Cancer Center), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Vicente Valero(The University of Texas MD Anderson Cancer Center), Hui Chen(The University of Texas MD Anderson Cancer Center), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Senthil Damodaran(The University of Texas MD Anderson Cancer Center), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k